FDA Promotes Personalized Medicine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Promotes Personalized Medicine



FDA is undertaking a spectrum of initiatives to encourage the development of drugs and medical products linked to patient subtypes. At a briefing to unveil a new report on these activities, commissioner Margaret Hamburg discussed how a deeper understanding of the underlying mechanisms of disease has made it possible for FDA to approve new cancer drugs for patients with specifically characterized tumors, as well as a new treatment for cystic fibrosis effective in patients with a specific gene mutation. Agency researchers are developing methods for refining dosing regimens by examining genetic factors that may affect how much of a drug enters the blood stream. Richard Pazdur, director of FDA’s Center for Drug Evaluation and Research’s Office of Oncology & Hematology products, predicted that smaller clinical trials for targeted cancer treatments will be possible by using platforms for universal testing of known biomarkers. “Paving the Way for Personalized Medicine” is available at www.fda.gov.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here